The Week in Review: Fosun Pharma Given OK for Hong Kong IPO
Shanghai Fosun Pharma received approval for a Hong Kong IPO that will raise between $600 million and $800 million; China Cord Blood Group announced Kohlberg Kravis Roberts will invest $65 million into the company; China Cord Blood also said it will build a $32 million stem cell biomedical engineering facility in Chongqing; Lee's Pharma in-licensed the China rights to a gastrointestinal-protective form of aspirin from PLx Pharma; Hainan Haiyao will spend $3.2 million to develop a cephalosporin antibiotic intermediate with Shanghai Knowshine; Lotus Pharmaceuticals' new Beijing headquarters has drained the company of cash, which may cause its delisting; and ThermoGenesis received SFDA approval for its BioArchive system, a device used for cryopreserving and archiving blood stem cells from umbilical cords. More details.... Stock Symbols: (SHA: 600196) (NYSE: CO) (HK: 950) (SHE: 000566) (OTCBB: LTUS) (NSDQ: KOOL) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});  
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here